TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance therapy TAIPEI, March 18, 2025 /PRNewswire/ -- TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regimen for...
Health in Tech Expands Executive Team to Drive Growth and Innovation
Dustin Plantholt appointed Chief Growth Officer Chris Kurtenbach appointed Chief Operating Officer (Jonathan) Del Lockett appointed Chief Strategy Officer Jenni Guerrica appointed Chief Information Security Officer STUART, Fla., March 18, 2025 /PRNewswire/ -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced key executive appointments to fuel growth, expand market opportunities,...
Health In Tech Announces Fourth Quarter and Full Year 2024 Financial Results
Total audited revenue for 2024 was $19.5 million. The first two months of 2025, our unaudited revenue is about $5.7million, more than 50% growth year over year for the first two months of 2024, and exceeded the revenue of the entire Q1 of 2024 Cash and cash equivalents were $7.8 million,...
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing the capabilities of its AI platform, GaluxDesign, in de novo antibody design. This research...
NEXTBIOMEDICAL, Fast Resorbable Microsphere ‘Nexsphere-F’ : Clinical Study Results on 155 Patients Published in the JVIR
Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating joint pain, have been published in the esteemed Journal of Vascular and Interventional Radiology (JVIR). Transcatheter...
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs
Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year 2024 Revenue Reached RMB39,241 Million, Up 5.2% Year-over-Year (Excluding COVID-19 Commercial Project of 2023) Full-Year Net Profit Attributable to the Owners of the Company Reached RMB9,450 Million, Diluted Earnings per Share (EPS) of RMB3.26 Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB10,583 Million, as...
Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia
SHANGHAI, March 17, 2025 /PRNewswire/ -- Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) for RN0361-an APOC3 targeted siRNA (small interfering RNA) therapeutic for severe hypertriglyceridemia (SHTG), mixed dyslipidemia, and familial chylomicronemia syndrome (FCS) treatment. The company plans to advance RN0361 development in HTG...
Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies
HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of financing. Heda Health Fund and Qihang Venture Capital participated in this round. The proceeds will support the advancement...
Healthcare Holding Schweiz Acquires Effectum CH-Rep (Switzerland)
Healthcare Holding Schweiz AG, a leading service provider and distributor of medical devices in Switzerland, is expanding its portfolio with the acquisition of Effectum CH-Rep AG. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH. BAAR, Switzerland, March 17, 2025 /PRNewswire/ -- Healthcare Holding Schweiz AG has successfully completed the acquisition of Effectum...
Fangzhou Inc.’s H2H Smart Healthcare Platform Honored as one of Guangdong’s Premier High-Tech Innovation Products
GUANGZHOU, China, March 17, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, today announced that its proprietary "H2H Smart Healthcare Innovation Platform" has been distinguished as a "2024 Guangdong Province Premier High-Quality and High-Tech Product" by the Guangdong High-Tech Industry Association. This prestigious...
